Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide. By developing innovative therapies that address the source of disease, not just the symptoms, scientists and physicians at Celgene are the driving force behind the creation of a broad, deep and diverse pipeline. The company has both a growing investment in the development of immunomodulatory agents and cell signalling inhibitors, as well as in the development of cellular and tissue therapeutics. These therapeutics are aimed at enabling Celgene to provide both physicians and clinicians with a more comprehensive and integrated set of solutions for managing complex human disorders such as cancer and immune-mediated inflammatory diseases.
Celgene is equally committed to patient support; with industry-leading programmes providing information, support and access to its innovative therapies, Celgene puts patients first.
For more information, please visit www.celgene.com.